Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. (Q53386515)

13 May 2018

title

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. (English)

1 reference

13 May 2018

author

Chris D Skedgel

2

1 reference

13 May 2018

Daniel Rayson

3

object named as

Daniel Rayson

1 reference

13 May 2018

author name string

Nathan W D Lamond

1

1 reference

13 May 2018

Lynn Lethbridge

4

1 reference

13 May 2018

Tallal Younis

5

1 reference

13 May 2018

language of work or name

English

0 references

publication date

24 February 2012

1 reference

13 May 2018

Breast Cancer Research and Treatment

published in

1 reference

13 May 2018

volume

133

1 reference

13 May 2018

page(s)

1115-1123

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s10549-012-1989-5

exact match

0 references

cites work

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Assessing the economic burden of breast cancer in a US managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

The costs of breast cancer prior to and following diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

International Web-based consultation on priorities for translational breast cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Estimates of the lifetime costs of breast cancer treatment in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

One thousand health-related quality-of-life estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Economic evaluations of leukemia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Preference-Based EQ-5D index scores for chronic conditions in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Willingness to pay for a quality-adjusted life year: in search of a standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Willingness to pay for a QALY: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

American Society of Clinical Oncology guidance statement: the cost of cancer care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Development of WHO guidelines on generalized cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1989-5

10.1007/S10549-012-1989-5

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

22361999

1 reference

13 May 2018